GVAX vaccine for prostate cancer: Phase III discontinued

Cell Genesys stopped the Phase III VITAL-2 trial of GVAX immunotherapy based on a recommendation by the study’s IDMC, which observed 67 deaths in the GVAX arm vs. 47 in the control arm. The internatio...